Zhongsheng Pharma's flu drug Onradesvir approved in China
Guangdong Zhongsheng Pharmaceutical (SZSE:002317) announced that its subsidiary, Zhongsheng Ruichuang Biotechnology, has received approval from China's National Medical Products Administration (NMPA) to market Onradesvir tablets (brand name: Anruiwei®; research code: ZSP1273). This innovative drug, a first-in-class influenza RNA polymerase PB2 protein inhibitor with global independent intellectual property rights, is indicated for treating uncomplicated influenza A in adults.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Guangdong Zhongsheng Pharmaceutical publishes news
Free account required • Unsubscribe anytime